Jerry Nadler

Co-Founder at DiaKine Therapeutics, Inc.

Jerry Nadler

Jerry Nadler

Co-Founder at DiaKine Therapeutics, Inc.

Biography

Dr. Jerry L. Nadler, MD, is Director & Chief Scientific Officer at DiaKine Therapeutics, Inc. and a Member at National Institutes of Health. He is on the Board of Directors at DiaKine Therapeutics, Inc. and Old Dominion University Research Foundation. Dr. Nadler was previously employed as Director-Diabetes & Endocrinology by City of Hope (California), a Member by Juvenile Diabetes Research Foundation International, and a Principal by University of Virginia. He also served on the board at Islet Sciences, Inc. He received his undergraduate degree from The State University of New York and a doctorate degree from the University of Miami (Florida).

Overview
Career Highlights

DiaKine Therapeutics, Inc.

RelSci Relationships

1493

Number of Boards

5

Birthday

1953

Age

67

Contact Data
Trying to get in touch with Jerry Nadler? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Jerry Nadler likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder & Managing Director at Tall Oaks Capital Partners LLC

Relationship likelihood: Strong

Chief Operating Officer & Director at DiaKine Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Aequus BioPharma, Inc.

Relationship likelihood: Strong

Co-Founder & Advisor at Avogadro Capital LLC

Relationship likelihood: Strong

Co-Founder at Freedom Meditech, Inc.

Relationship likelihood: Strong

Vice President at Eastern Virginia Medical School

Relationship likelihood: Average

Vice Dean, Research at Eastern Virginia Medical School

Relationship likelihood: Average

Co-Founder & Managing Director at Tall Oaks Capital Partners LLC

Relationship likelihood: Average

Co-Founder & Managing Partner at Tall Oaks Capital Partners LLC

Relationship likelihood: Average

Chief Executive Officer at Columbia Power Technologies, Inc.

Relationship likelihood: Average

Paths to Jerry Nadler
Potential Connections via
Relationship Science
You
Jerry Nadler
Co-Founder at DiaKine Therapeutics, Inc.
Career History
Co-Founder
2004 - ?

DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion.The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin.A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications.

Internal Medicine Chairman & Vice Dean of Research
Prior

Eastern Virginia Medical School (EVMS) is a public-private medical school in Norfolk, Virginia. Founded by grassroots efforts in the southeastern part of Virginia known as Hampton Roads, EVMS is not affiliated with an undergraduate institution and coordinates training through multiple medical centers in the Hampton Roads region. EVMS campus includes the 555-bed Sentara Norfolk General Hospital, the region's only tertiary level 1 trauma medical care facility, and the 212-bed Children's Hospital of The King's Daughters, a regional pediatric referral care facility and only stand-alone children's hospital in the state. EVMS is the first institution in the US to have produced a viable fetus through in vitro fertilization. EVMS is most known for its reproductive medicine, simulation/standardized-patient education as well as research in pediatrics, geriatrics, diabetes, and cancer. In addition, EVMS is well known for its leadership in community service and medical missions, as evidenced by faculty and alumni responsible for the founding of Operation Smile, Physicians for Peace, Global Brigades, and CONRAD.

Chief of Endocrinology & Metabolism
Prior

The University of Virginia (often abbreviated as UVA, UVa, or Virginia) is a public research university in Charlottesville, Virginia, United States. It was conceived and designed by U.S. President Thomas Jefferson, and established in 1819. UVA's initial Board of Visitors included former Presidents of the United States Thomas Jefferson, James Madison, and James Monroe. Monroe owned the initial site of the University, which was mostly farmland. His law office and farmhouse are now the site of Brown College at Monroe Hill, a residential college at UVA. UVA is one of the eight original Public Ivy universities, and it is the only university campus in the United States that is designated a World Heritage Site by UNESCO. In the 2013 edition of U.S. News and World Report's National University Rankings, the school was listed as America's 2nd best public university; tied with UCLA and surpassed only by UC Berkeley.

Boards & Committees
Member, Board of Directors
Prior
Investments
Details Hidden

DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion.The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin.A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jerry Nadler. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jerry Nadler's profile does not indicate a business or promotional relationship of any kind between RelSci and Jerry Nadler.